c-Met kinase inhibitors: an update patent review (2014-2017)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

c-Met kinase inhibitors: an update patent review (2014-2017)

Published:2018-12-12 Issue:1 Volume:29 Page:25-41
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Zhang Qing-Wen¹,Ye Zi-Dan¹,Shi Lei¹^ORCID

Affiliation:

1. Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China

Funder

Natural Science Foundation of Jiangsu Province

College Students Innovation Project for the R&D of Novel Drugs

National College Students’ innovation and entrepreneurship training program

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2019.1552261

Reference21 articles.

1. Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

2. Tyrosine kinase receptor indistinguishable from the c-met protein

3. C-MET inhibitors for advanced non-small cell lung cancer

4. The c-Met receptor: Implication for targeted therapies in colorectal cancer

5. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Simulation Study of Potential Inhibition of c‐Met Kinase Receptor by Phenoxy pyridine Derivatives: Based on QSAR, Molecular Docking, Molecular Dynamics;Chemistry & Biodiversity;2024-08-30

2. Brief Histories of Retroviral Integration Research and Associated International Conferences;Viruses;2024-04-13

3. Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors;Medicinal Chemistry of Anticancer Drugs;2023

4. THE PRECLINICAL JOURNEY OF MET INHIBITORS;2022 Medicinal Chemistry Reviews;2022-12-21

5. A computer-aided drug design approach to explore novel type II inhibitors of c-Met receptor tyrosine kinase for cancer therapy: QSAR, molecular docking, ADMET and molecular dynamics simulations;Journal of Biomolecular Structure and Dynamics;2022-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3